Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01091454 · ClinicalTrials.gov registry record · Phase 2
Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT01091454 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 48 participants.
The verdict
NCT01091454, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This phase II trial studies how well brostallicin and cisplatin work in treating patients with breast cancer that has spread to other parts of the body (metastatic) and does not have estrogen receptors, progesterone receptors, or large amounts of human epidermal growth factor receptor 2 (HER2) on its cells (triple-negative). Drugs used in chemotherapy, such as brostallicin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from spreading.
Interventions
- DRUG cisplatin
- DRUG brostallicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2010-06 |
| Est. Completion | 2014-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01091454
The ClinicalTrials.gov registry entry for NCT01091454 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cisplatin is the first listed.
NCT01091454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01091454 about?
NCT01091454 is a clinical study titled "Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer". This phase II trial studies how well brostallicin and cisplatin work in treating patients with breast cancer that has spread to other parts of the body (metastatic) and does not have estrogen receptors, progesterone receptors, or large amounts of human epidermal growth factor receptor 2 (HER2) on it...
What is the current status of trial NCT01091454?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2010-06. Estimated completion is 2014-11-01.
What interventions are being tested in trial NCT01091454?
The interventions under investigation include: cisplatin (DRUG), brostallicin (DRUG).
Who is sponsoring clinical trial NCT01091454?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.